Akari Therapeutics PLC (AKTX)
2.08
-0.15
(-6.73%)
USD |
NASDAQ |
Nov 15, 16:00
2.01
-0.07
(-3.37%)
After-Hours: 20:00
Akari Therapeutics Research and Development Expense (TTM): 8.848M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 8.848M |
| March 31, 2024 | 8.385M |
| June 30, 2023 | 8.246M |
| March 31, 2023 | 10.57M |
| June 30, 2022 | 8.411M |
| March 31, 2022 | 7.744M |
| December 31, 2021 | 9.134M |
| September 30, 2021 | 9.943M |
| June 30, 2021 | 8.780M |
| March 31, 2021 | 9.617M |
| December 31, 2020 | 8.820M |
| September 30, 2020 | 9.861M |
| June 30, 2020 | 13.22M |
| March 31, 2020 | 13.79M |
| December 31, 2019 | 8.739M |
| September 30, 2019 | 5.400M |
| June 30, 2019 | 6.941M |
| March 31, 2019 | 8.469M |
| Date | Value |
|---|---|
| December 31, 2018 | 11.80M |
| September 30, 2018 | 16.55M |
| June 30, 2018 | 19.63M |
| March 31, 2018 | 18.29M |
| December 31, 2017 | 23.29M |
| September 30, 2017 | 22.74M |
| June 30, 2017 | 20.15M |
| March 31, 2017 | 21.81M |
| December 31, 2016 | 17.31M |
| September 30, 2016 | 12.67M |
| June 30, 2016 | 10.19M |
| March 31, 2016 | 5.744M |
| December 31, 2015 | 5.799M |
| September 30, 2015 | 4.946M |
| June 30, 2015 | 3.795M |
| March 31, 2015 | 4.334M |
| December 31, 2014 | 3.579M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
7.744M
Minimum
Mar 2022
13.79M
Maximum
Mar 2020
9.607M
Average
8.848M
Median
Jun 2024
Research and Development Expense (TTM) Benchmarks
| DBV Technologies SA | 83.21M |
| Cellectis SA | 94.63M |
| Adaptimmune Therapeutics PLC | 143.17M |
| Biodexa Pharmaceuticals PLC | -- |
| NuCana PLC | 35.08M |